Patents Assigned to Leap Therapeutics, Inc.
  • Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
    Patent number: 11267876
    Abstract: A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: March 8, 2022
    Assignee: Leap Therapeutics, Inc.
    Inventors: Michael H. Kagey, Cynthia A. Sirard
  • USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY
    Publication number: 20190284264
    Abstract: A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 19, 2019
    Applicant: Leap Therapeutics, Inc.
    Inventors: Michael H. Kagey, Cynthia A. Sirard